Welcome to our dedicated page for Precipio SEC filings (Ticker: PRPO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Precipio, Inc. (PRPO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, quarterly reports, and other key documents filed with the U.S. Securities and Exchange Commission. As a NASDAQ-listed healthcare biotechnology company focused on cancer diagnostics, Precipio uses these filings to report on its financial performance, capital structure, and significant corporate events.
Investors can review Precipio’s periodic reports, such as its Quarterly Reports on Form 10-Q, which the company references in its earnings press releases. These filings contain detailed information on revenues from the pathology services and products divisions, gross margin trends, cash flow from operations, and non-GAAP measures such as EBITDA and Adjusted EBITDA, along with reconciliations to GAAP results. They also provide additional context on operating expenses, investments in laboratory and manufacturing capacity, and other factors influencing profitability.
Precipio’s current reports on Form 8-K highlight material events and investor communications. Recent 8-K filings have covered topics such as the termination of an at-the-market Sales Agreement with A.G.P./Alliance Global Partners, shareholder update calls, and the posting of an updated investor presentation. These filings often include press releases or presentation materials as exhibits, giving investors direct access to management’s commentary and strategic updates.
Through its filings, Precipio also discloses information about financing arrangements, warrant exercises, and debt obligations. For example, the company has reported on the termination of its ATM facility, the extent of shares sold under that agreement, and changes in its warrant structure. Press releases referenced in filings further describe the repayment of a Change Healthcare advance and the remaining small loan with the Connecticut Department of Economic and Community Development, providing insight into the company’s debt profile.
On Stock Titan, these SEC documents are supplemented by AI-powered tools that help interpret complex filings. Investors can use AI-generated summaries to understand the main points of lengthy 10-Q or 10-K reports, track Form 8-K events, and quickly identify disclosures related to revenue composition, margins, capital structure changes, and other topics relevant to a specialty cancer diagnostics company like Precipio.
Precipio, Inc. (PRPO) reported an insider stock purchase by its Chief Operating Officer. On 07/08/2025, the COO acquired 31 shares of common stock in an open-market transaction at $16.3 per share, increasing the directly held position to 690 shares. The filing notes that these shares are being purchased under a pre-established Rule 10b5-1 trading plan adopted by the reporting person, which is designed to provide an affirmative defense against insider trading claims when trading while in possession of material nonpublic information.
Precipio, Inc. (PRPO) reported Q3 2025 results. Net sales were $6,767 thousand, up from $5,209 thousand a year ago, driven by higher diagnostic testing revenue from Medicare and third-party payers. Gross profit rose to $3,005 thousand. Operating loss narrowed to $61 thousand and net loss improved to $79 thousand from $626 thousand.
For the nine months, net sales were $17,350 thousand versus $13,082 thousand, with net loss improving to $889 thousand from $3,925 thousand. Cash at quarter-end was $2,305 thousand, aided by $1,260 thousand of warrant exercise proceeds and $319 thousand provided by operating activities. The company disclosed “substantial doubt” about its ability to continue as a going concern over the next twelve months. As of November 11, 2025, common shares outstanding were 1,752,007.
Precipio, Inc. (PRPO) announced it will host a Q3‑2025 Shareholder Update Call on November 17, 2025 at 5:00 PM ET. The call will include updates on all of the company’s current core businesses.
The company furnished a press release as Exhibit 99.1. The information, including the exhibit, is being furnished and is not deemed filed under the Exchange Act.
Precipio, Inc. (PRPO) reported an insider stock transaction by a director. On October 15, 2025, the director acquired 746 shares of common stock at $17.58 per share. The grant was issued as consideration in lieu of cash compensation for service on the Board of Directors for Q3-25.
Following this transaction, the director beneficially owns 53,572 shares, held directly.
Precipio, Inc. (PRPO) reported an insider transaction by a director. On 10/15/2025, the director acquired 568 shares of common stock in a transaction coded “A,” reflecting a grant in lieu of cash compensation for Board service for Q3‑25. The filing lists a price of $17.58.
Following this grant, the director’s beneficial ownership stands at 15,708 shares, held directly. This is a routine equity compensation event and does not indicate a public offering or company-level capital raise.
Precipio (PRPO): A company director reported acquiring 597 shares of common stock on October 15, 2025 at $17.58 per share. The shares were granted as equity in lieu of cash compensation for service on the Board for Q3-25.
Following the transaction, the reporting person beneficially owns 15,247 shares, held directly.
Precipio (PRPO) director Kathleen D. LaPorte reported acquiring 711 shares of common stock on October 15, 2025 at $17.58 per share. The grant was issued in lieu of cash compensation for service on the Board of Directors for Q3-25.
After this transaction, LaPorte directly owns 6,862 shares of Precipio common stock.
Leviticus Partners LP reports beneficial ownership of 130,000 shares of Precipio, Inc. common stock, representing 8.0% of the class. The filing states the shares are held with sole voting and dispositive power and were acquired and are held in the ordinary course of business, not for the purpose of changing control of the issuer. The filing is signed by Adam M Hutt as Managing Member and dated 09/22/2025. No group affiliations, subsidiaries, or additional arrangements are disclosed.
Kathleen LaPorte, a director of Precipio, Inc. (PRPO), reported the sale of 6,152 shares of the issuer's common stock on 09/08/2025 at a weighted average price of $20.06 per share. After the reported disposals, she beneficially owned 6,151 shares. The shares were originally granted to Ms. LaPorte on 04/15/2024 as consideration in lieu of cash for board service covering Q1 2023 through Q1 2024; that grant was approved by the board under Rule 16b-3 and is exempt from Section 16(b). The Form 4 is signed by Ms. LaPorte on 09/10/2025. The filing notes the shares were sold in multiple transactions at prices ranging from $20.00 to $20.50.
Form 144 notice for Precipio, Inc. (PRPO): A holder plans to sell 6,152 shares of Common stock through Morgan Stanley Smith Barney, with an aggregate market value of $123,384.51. The shares represent part of 1,619,584 shares outstanding and the proposed approximate sale date is 09/08/2025.
The shares were acquired on 04/15/2024 as board compensation and paid as compensation. The filer reports no sales in the past three months and certifies no undisclosed material information.